File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine

TitleHepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine
Authors
Issue Date2003
PublisherInternational Medical Press. The Journal's web site is located at http://www.intmedpress.com/Journals/AVT/journals_avt_home.cfm
Citation
Antiviral Therapy, 2003, v. 8 n. 6, p. 531-534 How to Cite?
AbstractTo date, there have been no studies examining the role of hepatitis B virus (HBV) genotypes on the response to lamivudine therapy and the development of YMDD mutations. The present study aimed at determining any differences in the antiviral response and risk of YMDD mutations between lamivudine-treated patients with HBV genotype B and genotype C. Eighty-two patients receiving lamivudine were recruited. HBV genotypes at baseline and YMDD mutations at week 52 were determined by line probe assays (LiPA). HBV DNA levels were determined by the Cobas Amplicor HBV Monitor Test. Seventeen (20.7%) and sixty-four (78%) patients had single genotypes of B and C, respectively. At both week 24 and 52 there were no differences in the median reduction of HBV DNA levels (median 4 logs drop), the median reduction of alanine aminotransferase (ALT) levels, and the proportion with normalization of ALT [8/8 (100%) vs 26/37 (70.3%), P=0.19] between patients with genotypes B and C. The rate of HBeAg seroconversion [3/17 (17.6%) vs 6/64 (9.4%), P=0.39] and the chance of YMDD mutation development [3/17 [17.6%) vs 12/64 [18.8%), P=1.0] at week 52 were also similar between patients with genotype B and C, respectively. In conclusion, there was no difference in the antiviral response and the rate of development of YMDD mutations in Chinese patients with genotype B and C after 1 year of lamivudine. Determination of HBV genotypes before lamivudine therapy was probably not an important pretreatment investigation to predict antiviral responses in Chinese patients.
Persistent Identifierhttp://hdl.handle.net/10722/76492
ISSN
2015 Impact Factor: 2.916
2015 SCImago Journal Rankings: 1.361
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorSablon, Een_HK
dc.contributor.authorYuan, HJen_HK
dc.contributor.authorSum, SMen_HK
dc.contributor.authorHui, CKen_HK
dc.contributor.authorChan, AOOen_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-06T07:21:49Z-
dc.date.available2010-09-06T07:21:49Z-
dc.date.issued2003en_HK
dc.identifier.citationAntiviral Therapy, 2003, v. 8 n. 6, p. 531-534en_HK
dc.identifier.issn1359-6535en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76492-
dc.description.abstractTo date, there have been no studies examining the role of hepatitis B virus (HBV) genotypes on the response to lamivudine therapy and the development of YMDD mutations. The present study aimed at determining any differences in the antiviral response and risk of YMDD mutations between lamivudine-treated patients with HBV genotype B and genotype C. Eighty-two patients receiving lamivudine were recruited. HBV genotypes at baseline and YMDD mutations at week 52 were determined by line probe assays (LiPA). HBV DNA levels were determined by the Cobas Amplicor HBV Monitor Test. Seventeen (20.7%) and sixty-four (78%) patients had single genotypes of B and C, respectively. At both week 24 and 52 there were no differences in the median reduction of HBV DNA levels (median 4 logs drop), the median reduction of alanine aminotransferase (ALT) levels, and the proportion with normalization of ALT [8/8 (100%) vs 26/37 (70.3%), P=0.19] between patients with genotypes B and C. The rate of HBeAg seroconversion [3/17 (17.6%) vs 6/64 (9.4%), P=0.39] and the chance of YMDD mutation development [3/17 [17.6%) vs 12/64 [18.8%), P=1.0] at week 52 were also similar between patients with genotype B and C, respectively. In conclusion, there was no difference in the antiviral response and the rate of development of YMDD mutations in Chinese patients with genotype B and C after 1 year of lamivudine. Determination of HBV genotypes before lamivudine therapy was probably not an important pretreatment investigation to predict antiviral responses in Chinese patients.en_HK
dc.languageengen_HK
dc.publisherInternational Medical Press. The Journal's web site is located at http://www.intmedpress.com/Journals/AVT/journals_avt_home.cfmen_HK
dc.relation.ispartofAntiviral Therapyen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAlanine Transaminase - blooden_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshDrug Resistance, Viralen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGene Products, pol - geneticsen_HK
dc.subject.meshGenotypeen_HK
dc.subject.meshHepatitis B - drug therapy - virologyen_HK
dc.subject.meshHepatitis B virus - classification - geneticsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMutationen_HK
dc.titleHepatitis B virus genotypes B and C do not affect the antiviral response to lamivudineen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1359-6535&volume=8&spage=531&epage=534&date=2003&atitle=Hepatitis+B+Virus+Genotypes+B+and+C+Do+Not+Affect+The+Antiviral+Response+To+Lamivudineen_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailWong, DKH:danywong@hku.hken_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid14760886-
dc.identifier.scopuseid_2-s2.0-0242652645en_HK
dc.identifier.hkuros87523en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0242652645&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume8en_HK
dc.identifier.issue6en_HK
dc.identifier.spage531en_HK
dc.identifier.epage534en_HK
dc.identifier.isiWOS:000231266900004-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridWong, DKH=7401535819en_HK
dc.identifier.scopusauthoridSablon, E=6603694538en_HK
dc.identifier.scopusauthoridYuan, HJ=7402446707en_HK
dc.identifier.scopusauthoridSum, SM=6603889132en_HK
dc.identifier.scopusauthoridHui, CK=7202876933en_HK
dc.identifier.scopusauthoridChan, AOO=7403167965en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats